(Total Views: 377)
Posted On: 09/04/2019 9:16:41 AM
Post# of 154850
Maybe I've been reading The Onion too long, but I've started to see extra words in CYDY's PR headlines:
"CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab, IS STILL BROKE"
Don't get me wrong, I am very pleased with today's news. It's unequivocally positive that leronlimab has another potential indication.
However, none of the more-recent developments (colon cancer IND, NASH IND, PREP, etc.) will matter until financing is settled.
Would love to be wrong and watch us be up 25% today, but we all know that isn't in the cards.
"CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab, IS STILL BROKE"
Don't get me wrong, I am very pleased with today's news. It's unequivocally positive that leronlimab has another potential indication.
However, none of the more-recent developments (colon cancer IND, NASH IND, PREP, etc.) will matter until financing is settled.
Would love to be wrong and watch us be up 25% today, but we all know that isn't in the cards.
(3)
(0)
